Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 5
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
RET fusion
gastric cancer · Immune Checkpoint Inhibitor
RET fusion is flagged as trial selection rising because public trials show inclusion required evidence in 7 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 10
Common snippets: MSI-h | MSI-h | MSI-h
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: Medium
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT03647969 | https://clinicaltrials.gov/study/NCT05535569 | https://clinicaltrials.gov/study/NCT02589496 | https://clinicaltrials.gov/study/NCT03894618 | https://clinicaltrials.gov/study/NCT02952989 | https://clinicaltrials.gov/study/NCT04006262 | https://clinicaltrials.gov/study/NCT06901531